$-0.11
(Market cap
$1,862 Mln
Revenue (TTM)
$1,044 Mln
P/E Ratio
3.2
P/B Ratio
0.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-31.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$7.4
-
Face value
--
-
Shares outstanding
65,897,071
10 Years Aggregate
CFO
€1,145.47 Mln
EBITDA
€-407.72 Mln
Net Profit
€-469.02 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Galapagos NV - ADR
| -14.3 | -1.5 | -16.8 | -2.1 | -12.2 | -17.6 | -7.3 |
|
BSE Sensex*
| -9.9 | 1.1 | 2.3 | -6.0 | 6.4 | 7.7 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Galapagos NV - ADR
| 18.9 | -32.1 | -8.4 | -19.5 | -44.3 | -52.1 | 125.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Galapagos NV - ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and... systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium. Read more
-
CEO, Chairman, Interim Head of R&D
Dr. Paulus A. Stoffels M.D., Ph.D.
-
CEO, Chairman, Interim Head of R&D
Dr. Paulus A. Stoffels M.D., Ph.D.
-
Headquarters
Mechelen
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Galapagos NV - ADR
What is the current share price of Galapagos NV - ADR Today?
The share price of Galapagos NV - ADR is $28.02 (NASDAQ) as of 05-Jun-2026 09:30 EDT. Galapagos NV - ADR has given a return of -12.24% in the last 3 years.
What is the current PB & PE ratio of Galapagos NV - ADR?
The P/E ratio of Galapagos NV - ADR is 3.18 times as on 05-Jun-2026.
The P/B ratio of Galapagos NV - ADR is 0.49 times as on 05-Jun-2026, a 90 discount to its peers’ median range of 4.96 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
6.71
|
0.67
|
|
2024
|
24.81
|
0.63
|
|
2023
|
12.68
|
0.96
|
|
2022
|
-13.40
|
1.16
|
|
2021
|
-29.25
|
1.39
|
What is the 52 Week High and Low of Galapagos NV - ADR?
The 52-week high and low of Galapagos NV - ADR are Rs 37.78 and Rs 26.42 as of 15-Jun-2026.
What is the market cap of Galapagos NV - ADR?
Galapagos NV - ADR has a market capitalisation of $ 1,862 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Galapagos NV - ADR?
Before investing in Galapagos NV - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.